ctDNA Assay in Patients With Resectable Pancreatic Cancer

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT05052671
Status
Recruiting
Apply to this trial

Conditions

  • Pancreas Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.

Key Dates

Start date
May 25, 2022
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2028

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

ctDNA Positivity in Patients with Resectable Pancreatic Cancer [ Time Frame: Baseline ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
University of OklahomaOklahoma CityOklahoma73117
Lead Nurse
[email protected]
405-271-8777
Sagila George, MD (PRINCIPAL_INVESTIGATOR)
Stephenson Cancer Center- TulsaTulsaOklahoma74104
Laura K Brett, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Oklahoma City, OK

By research site
University of Oklahoma· Oklahoma City, OKStephenson Cancer Center- Tulsa· Tulsa, OK

Related Studies